N/A
N=10
Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Bottom Line
View on ClinicalTrials.gov: NCT06571760 ↗Enrolled (actual)
10
Serious AEs
10.0%
Results posted
May 2026
Primary outcome: Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Vertex Pulmonary Embolectomy System (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Neptune Medical
- Primary completion
- Apr 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Right Ventricle/Left Ventricle (RV/LV) Ratio |
-0.4 | — |
| PRIMARY Major Adverse Events (MAEs) |
0; 10 | — |
Summary
This study study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of pulmonary embolism.
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years 0.9 on CTA as assessed by investigator (site determined).
- Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
- Subject is willing and able to provide written informed consent prior to receiving any non-standard of care clinical investigation plan specific procedures
- Subject is willing and able to comply with all clinical investigation plan required follow-up visits
Exclusion Criteria
- Thrombolytic use within 30 days of baseline CTA
- Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
- Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
- Unstable heart rate > 130 beats per minute prior to procedure
- FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
- Hematocrit 1.8 mg/dL
- International normalized ratio (INR) > 3
- Major trauma injury severity score (ISS) > 15 within the past 14 days
- Presence of intracardiac lead in the right ventricle or right atrium placed <180 days prior to the index procedure
- Cardiovascular or pulmonary surgery within last 30 days
- Actively progressing cancer requiring chemotherapy
- Known bleeding diathesis or coagulation disorder
- Left bundle branch block
- History of severe or chronic pulmonary arterial hypertension
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
- History of decompensated heart failure
- Patients on extracorporeal membrane oxygenation (ECMO)
- History of underlying lung disease that is oxygen dependent
- History of chest irradiation
- History of heparin-induced thrombocytopenia (HIT)
- Contraindication to systemic or therapeutic doses of heparin or anticoagulants
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention
- Life expectancy of < 365 days, as determined by Investigator
- Female who is pregnant or nursing
- Current participation in another investigational drug or device treatment study
- Inability to lay flat for procedure
- Known presence of right-to-left cardiac shunt
- History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
- Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
Data sourced from ClinicalTrials.gov (NCT06571760). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.